<DOC>
	<DOCNO>NCT01292226</DOCNO>
	<brief_summary>This study evaluate correlation pharmacokinetic pharmacodynamic parameter CellCept patient undergo primary kidney transplantation , order assess impact clinical outcome risk acute rejection . All patient receive oral CellCept , 1g twice daily , pharmacokinetic pharmacodynamic parameter measure week 2 , 4 , 12 24 . The anticipated time study treatment 24 week .</brief_summary>
	<brief_title>A Study Correlation Between Pharmacokinetic Pharmacodynamic Parameters CellCept ( Mycophenolate Mofetil ) .</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Adult patient , 18 65 year age Patients undergoing primary kidney transplantation Recipients multiple organ transplant Prior therapy CellCept Presence history malignancy , except successfully treat basal squamous cell carcinoma skin Active peptic ulcer active serious digestive system disease may affect absorption CellCept</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>